Biotek-snakken — September 2024
-
ACARIX: VD AAMIR MAHMOOD KÖPT NÄRMARE 2,3 MLN AKTIER
I dag kl. 09:57 ∙ Nyhetsbyrån Direkt
STOCKHOLM (Nyhetsbyrån Direkt) Medicinteknikbolaget Acarix vd Aamir Mahmood har köpt närmare 2,3 miljoner aktier i bolaget den 29 och den 30 augusti för totalt drygt 0,6 miljoner kronor.Det framgår av ett pressmeddelande.
Affärerna gjordes till en snittkurs om 0:2866 kronor.
Efter transaktionerna uppgår Aamir Mahmoods innehav i Acarix till drygt 5,4 miljoner aktier.
-
Nationally Recognized Cardiology Practice Places Multiunit Order of the Acarix CADScor System
I dag kl. 10:35 ∙ MFN
Acarix, a leader in rapid AI and acoustics-based cardiac diagnostics, is pleased to announce that Connected Cardiovascular Care Associates (C3), the first U.S. cardiology practice dedicated exclusively to the digital monitoring of cardiac conditions, has placed a four-unit order of the CADScor System. -
The CADScor System will complement C3's suite of digital wearable devices, including smartwatches, digital blood pressure monitors, and weight scales, solidifying the practice's commitment to innovative, patient-centric care. This approach allows for continuous monitoring and early intervention, crucial for managing conditions such as heart blockages, rhythm problems, weakened heart function, and vascular issues like leg blockages or vein problems.
-
ARCTIC BIOSCIENCE: ABG kutter kursmålet til NOK 17 (54), gjentar kjøp. Det veritable kuttet forklarer de med bytte av analytiker. (den har nok neppe vært fulgt opp særlig siden siste analyse.. )
-
@Rasbom - okay
I dag købte jeg i intervallet fra kurs 32 ned til næsten kurs 22, og fik derved forøget min IBT-position med næsten 128%. Solgte herefter ca. 33% af min totale position omkring kurs ca. 37,5. Den solgte position havde et GAK på præcis kurs 27,4. Spændende hvad morgendagen bringer -
3 Monster Biotech Stocks to Buy Before 2025 https://proinvestor.com/investornyt/1208380/3-monster-biotech-stocks-to-buy-before-2025
-
Godmorgen
-
Ascendis Pharma Reaches $150 Mln Royalty Funding Agreement With Royalty Pharma; Stock Drops https://proinvestor.com/investornyt/1208915/ascendis-pharma-reaches-150-mln-royalty-funding-agreement-with-royalty-pharma-stock-drops
-
Ascelia Pharma: Secures full support from the completed Rights Issue
The preliminary result is 100% support and a gross proceed of SEK 105m. This outcome also adds future support from warrants due in spring 2025, adding SEK 30m gross (based on today’s share price).
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind